Cidara Therapeutics Inc (CDTX)vsInsmed Inc (INSM)
CDTX
Cidara Therapeutics Inc
$221.38
0.00%
HEALTHCARE · Cap: $6.96B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
CDTX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CDTX
Avoid23
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Trading at 15.4x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDTX
The strongest argument for CDTX centers on Debt/Equity.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CDTX
The primary concerns for CDTX are Price/Book, EPS Growth, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CDTX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CDTX carries more volatility with a beta of 1.53 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CDTX generates stronger free cash flow (-41M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cidara Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cidara Therapeutics, Inc., a biotechnology company, is focused on the discovery, development, and commercialization of new long-acting anti-infectives for the treatment and prevention of disease in the United States. The company is headquartered in San Diego, California.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?